Multiple Myeloma

The addition of statin medications to contemporary therapies like ibrutinib could significantly improve survival for patients with certain hematologic malignancies, according to results of a retrospective study.

More than half of patients recently diagnosed with lymphoma or myeloma had clinically significant symptoms of anxiety or depression, according to study results.

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, according to an industry press release.

The addition of subcutaneous daratumumab to triplet therapy improved outcomes for certain patients with newly diagnosed multiple myeloma, study results showed.

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, according to a press release from Celltrion.

The FDA has approved two new biosimilars of denosumab to treat osteoporosis, increase bone mass, prevent skeletal-related events for people with multiple myeloma and other indications, Samsung Bioepis announced.